{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:03:21Z","timestamp":1772136201257,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Austria started its COVID-19-vaccination program in December 2020 with three different vaccines. As the vaccination program continues, we encountered increased 2-[18F] FDG-activity not only in axillary lymph nodes ipsilateral to the injection site but also in other organs. The aim of this retrospective study is to present results of the metabolic activity of ipsilateral axillary lymph nodes, liver, blood pool, spleen, and bone marrow after three different vaccines. To our knowledge, this is the first study to examine systemic response changes in relation to time after COVID-19 vaccination using three different vaccines. The collected data of 220 eligible vaccinated patients (127 with BioNTech\/Pfizer BNT162b2, 61 with Moderna, and 32 with AstraZeneca) examined with 2-[18F] FDG-PET\/CT were enrolled. The PET\/CT examinations were evaluated from day 1 to day 135 (SD: 23.2, median: 26) after different vaccinations. Seventy-one out of these 220 patients underwent a pre-vaccination 2-[18F] FDG -PET\/CT. SUVmax of axillary node(s), and blood pool, liver, spleen, and bone marrow as reference organs were calculated. The ratio of SUVmax activity of axillary lymph node to reference organs was also compared in all patients. The tracer activity dynamics were investigated in three different vaccines. After BioNTech\/Pfizer vaccination 2-[18F] FDG activity in axillary lymph nodes shows a steady decrease in all patients. Ten days after vaccination the 2-[18F] FDG uptake was at its highest activity. Seventy days after vaccination, tracer activity is not different from the background activity of 2-[18F] FDG in the axillary region. This result also applies to other two vaccines; however, in the 4th week after Moderna vaccination SUVmax in lymph nodes showed the highest peak of tracer activity. With AstraZeneca the highest activity was at the earlier days. There was no significant statistical difference of SUVmax of lymph nodes or its ratios to other reference organs between three groups of vaccines. SUVmax in lymph nodes was statistically significant lower than SUVmax in the liver, spleen, and bone marrow with\n                    <jats:italic>p<\/jats:italic>\n                    -values of\u2009&lt;\u20090.001, 0.044, and 0.001, respectively. In the group of 71 patients with a pre-vaccination PET\/CT examination, the median SUVmax of lymph nodes increased significantly after vaccination from 0.82 (IQR 0.59\u20131.38) to 1.80 (IQR 1.07\u20133.89)(\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). In contrast median tracer activity in the liver decreased from 3.37 (IQR 2.83\u20133.91) to 3.11 (2.56\u20133.70) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.032). There was no significant change of tracer activity after vaccination in other reference regions (mediastinum, spleen, and bone marrow). In this group of 71 patients, there was also no significant difference in tracer activity in different types of vaccines. Local site and ipsilateral axillary lymph node activity in 2-[18F] FDG PET\/CT after COVID19-vaccination is suggested in many studies. The main challenge is recognizing the changes in lymph nodes during time after vaccination to minimize false interpretation, foremost in patients with oncological diagnoses. Moreover, different vaccines cause different system metabolic changes. The knowledge of vaccine type, the time interval between vaccination and PET\/CT scan is essential, especially in therapy evaluation.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-49376-8","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T09:02:31Z","timestamp":1702112551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The systemic impact of different COVID-19 vaccines in 2-[18F] FDG-PET\/CT"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3539-8771","authenticated-orcid":false,"given":"Tina","family":"Nazerani-Zemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Pernthaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerold","family":"Schwantzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gstettner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"issue":"50","key":"49376_CR1","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","volume":"69","author":"SE Oliver","year":"2020","unstructured":"Oliver, S. E. et al. The advisory committee on immunization practices\u2019 interim recommendation for use of pfizer-BioNTech COVID-19 vaccine\u2014United States, December 2020. MMWR Morb. Mortal. Wkly. Rep. 69(50), 1922\u20131924 (2020).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"49376_CR2","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","volume":"69","author":"S Oliver","year":"2021","unstructured":"Oliver, S. et al. The advisory committee on immunization practices\u2019 interim recommendation for use of moderna COVID-19 vaccine\u2014United States, December 2020. MMWR Morb. Mortal. Wkly. Rep. 69, 1653\u20131656 (2021).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"49376_CR3","unstructured":"Pfizer-BioNTech COVID-19 Vaccine: US Food and Drug Administration. 2021. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease2019-covid-19\/pfizer-biontech-covid-19-vaccine."},{"key":"49376_CR4","unstructured":"Moderna COVID-19 Vaccine: US Food and Drug Administration. Accessed 5 February 2021; https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease2019-covid-19\/moderna-covid-19-vaccine."},{"issue":"10249","key":"49376_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396(10249), 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"49376_CR6","unstructured":"Die ersten Menschen in \u00d6sterreich erhielten Covid-Vakzine; Medizinische Universit\u00e4t Wien (2020); https:\/\/www.meduniwien.ac.at\/web\/ueber-uns\/news\/detailseite\/2020\/news-im-dezember-2020\/die-ersten-menschen-in-oesterreich-erhielten-covid-vakzine\/."},{"key":"49376_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/RLU.0000000000001603","volume":"42","author":"EE Coates","year":"2017","unstructured":"Coates, E. E. et al. Lymph node activation by PET\/CT following vaccination with licensed vaccines for human papillomaviruses. Clin. Nucl. Med. 42, 329\u2013334 (2017).","journal-title":"Clin. Nucl. Med."},{"key":"49376_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12149-011-0568-x","volume":"26","author":"N Shirone","year":"2012","unstructured":"Shirone, N. et al. Axillary lymph node accumulation on FDG-PET\/CT after influenza vaccination. Ann. Nucl. Med. 26, 248\u2013252 (2012).","journal-title":"Ann. Nucl. Med."},{"key":"49376_CR9","volume-title":"Local reactions, systemic reactions, adverse events, and serious adverse events: Moderna COVID-19 vaccine","author":"Centers for Disease Control and Prevention","year":"2020","unstructured":"Centers for Disease Control and Prevention. Local reactions, systemic reactions, adverse events, and serious adverse events: Moderna COVID-19 vaccine (Centers for Disease Control and Prevention, 2020)."},{"key":"49376_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2214\/AJR.21.25651","volume":"217","author":"S Mortazavi","year":"2021","unstructured":"Mortazavi, S. Coronavirus disease (COVID-19) vaccination associated axillary adenopathy: Imaging findings and follow-up recommendations in 23 women. AJR Am. J. Roentgenol. 217, 857\u2013858 (2021).","journal-title":"AJR Am. J. Roentgenol."},{"key":"49376_CR11","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.acra.2021.04.007","volume":"28","author":"P Keshavarz","year":"2021","unstructured":"Keshavarz, P. et al. Lymphadenopathy following COVID-19 vaccination: Imaging findings review. Acad. Radiol. 28, 1058\u20131071 (2021).","journal-title":"Acad. Radiol."},{"key":"49376_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40336-021-00430-3","volume":"9","author":"G Treglia","year":"2021","unstructured":"Treglia, G. et al. PET findings after COVID-19 vaccination: \u201cKeep Calm and Carry On\u201d. Clin. Transl. Imaging 9, 209\u2013214 (2021).","journal-title":"Clin. Transl. Imaging"},{"issue":"4","key":"49376_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3390\/diagnostics11040676","volume":"11","author":"R-D Seban","year":"2021","unstructured":"Seban, R.-D. et al. Immune response visualized in vivo by [18F]-FDG PET\/CT after COVID-19 vaccine. Diagnostics 11(4), 676 (2021).","journal-title":"Diagnostics"},{"key":"49376_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(21)00464-5","volume":"397","author":"J Steinberg","year":"2021","unstructured":"Steinberg, J., Thomas, A. & Iravani, A. 18F-fluorodeoxyglucose PET\/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine. Lancet 397, 9 (2021).","journal-title":"Lancet"},{"key":"49376_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard, R. et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: Version 2.0. Eur. J. Nucl. Med. Mol. Imaging 42, 328\u2013354 (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"49376_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.4103\/ijnm.ijnm_31_21","volume":"36","author":"S Usmani","year":"2021","unstructured":"Usmani, S. et al. Fluorine-18 fluorodeoxyglucose positron emission tomography\/computed tomography in Hodgkin\u2019s lymphoma: Diagnostic challenge during COVID vaccination. Indian J. Nucl. Med. 36, 343\u2013346 (2021).","journal-title":"Indian J. Nucl. Med."},{"issue":"2","key":"49376_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/RLU.0000000000003847","volume":"47","author":"J Brophy","year":"2021","unstructured":"Brophy, J., Henkle, G. & Rohren, E. M. DOTATATE uptake in an axillary lymph node after COVID-19 vaccination. Clin. Nucl. Med. 47(2), 174\u2013175 (2021).","journal-title":"Clin. Nucl. Med."},{"key":"49376_CR18","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/RLU.0000000000003683","volume":"46","author":"AH Brown","year":"2021","unstructured":"Brown, A. H. et al. The challenge of staging breast cancer with PET\/CT in the era of COVID vaccination. Clin. Nucl. Med. 46, 1006\u20131010 (2021).","journal-title":"Clin. Nucl. Med."},{"issue":"2","key":"49376_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/RLU.0000000000003844","volume":"47","author":"FC Wong","year":"2021","unstructured":"Wong, F. C. et al. 18F-fluciclovine-avid reactive axillary lymph nodes after COVID-19 vaccination. Clin. Nucl. Med. 47(2), 154\u2013155 (2021).","journal-title":"Clin. Nucl. Med."},{"key":"49376_CR20","doi-asserted-by":"publisher","first-page":"690443","DOI":"10.3389\/fonc.2021.690443","volume":"11","author":"R Czepczy\u0144ski","year":"2021","unstructured":"Czepczy\u0144ski, R. et al. Interference of COVID-19 vaccination With PET\/CT leads to unnecessary additional imaging in a patient with metastatic cutaneous melanoma-case report. Front. Oncol. 11, 690443 (2021).","journal-title":"Front. Oncol."},{"issue":"1","key":"49376_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.2967\/jnumed.121.262194","volume":"63","author":"M Eifer","year":"2021","unstructured":"Eifer, M. et al. COVID-19 mRNA vaccination: Age and immune status and its association with axillary lymph node PET\/CT uptake. J. Nucl. Med. 63(1), 134\u2013139 (2021).","journal-title":"J. Nucl. Med."},{"key":"49376_CR22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2214\/AJR.21.25728","volume":"217","author":"LJ McIntosh","year":"2021","unstructured":"McIntosh, L. J. et al. COVID-19 vaccination-related uptake on FDG PET\/CT: An emerging dilemma and suggestions for management. AJR Am. J. Roentgenol. 217, 975\u2013983 (2021).","journal-title":"AJR Am. J. Roentgenol."},{"issue":"5","key":"49376_CR23","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/CMR.0000000000000768","volume":"31","author":"A Indini","year":"2021","unstructured":"Indini, A. et al. COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: A case report. Melanoma Res. 31(5), 490\u2013493 (2021).","journal-title":"Melanoma Res."},{"issue":"2","key":"49376_CR24","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1097\/RLU.0000000000003951","volume":"47","author":"D Albano","year":"2021","unstructured":"Albano, D. et al. COVID-19 vaccination manifesting as unilateral lymphadenopathies detected by 18F-choline PET\/CT. Clin. Nucl. Med. 47(2), e187\u2013e189 (2021).","journal-title":"Clin. Nucl. Med."},{"key":"49376_CR25","first-page":"1","volume":"22","author":"DG Schroeder","year":"2021","unstructured":"Schroeder, D. G. et al. Frequency and characteristics of nodal and deltoid FDG and 11C-choline uptake on PET performed after COVID-19 vaccination. AJR Am. J. Roentgenol. 22, 1\u201311 (2021).","journal-title":"AJR Am. J. Roentgenol."},{"issue":"11","key":"49376_CR26","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1007\/s00259-021-05389-x","volume":"48","author":"D Cohen","year":"2021","unstructured":"Cohen, D. et al. Correlation between BNT162b2 mRNA COVID-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. Eur. J. Nucl. Med. Mol. Imaging 48(11), 3540\u20133549 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"49376_CR27","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s00259-021-05314-2","volume":"48","author":"D Cohen","year":"2021","unstructured":"Cohen, D. et al. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA COVID-19 vaccine: Incidence assessed by [18F]FDG PET-CT and relevance to study interpretation. Eur. J. Nucl. Med. Mol. Imaging 48, 1854\u20131863 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"49376_CR28","first-page":"20210040","volume":"7","author":"S Shah","year":"2021","unstructured":"Shah, S. et al. COVID-19 vaccine-related lymph node activation: Patterns of uptake on PET-CT. BJR Case Rep. 7(3), 20210040 (2021).","journal-title":"BJR Case Rep."},{"key":"49376_CR29","doi-asserted-by":"publisher","first-page":"3018349","DOI":"10.1155\/2019\/3018349","volume":"2019","author":"G Treglia","year":"2019","unstructured":"Treglia, G. Diagnostic performance of 18F-FDG PET\/CT in infectious and inflammatory diseases according to published meta-analyses. Contrast Med. Mol. Imaging 2019, 3018349 (2019).","journal-title":"Contrast Med. Mol. Imaging"},{"issue":"45","key":"49376_CR30","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.3346\/jkms.2021.36.e312","volume":"36","author":"JW Park","year":"2021","unstructured":"Park, J. W. et al. Multisystem inflammatory syndrome in an adult after COVID-19 vaccination: A case report and literature review. J. Korean Med. Sci. 36(45), e312 (2021).","journal-title":"J. Korean Med. Sci."},{"key":"49376_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","volume":"44","author":"SF Barrington","year":"2017","unstructured":"Barrington, S. F. & Kluge, R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur. J. Nucl. Med. Mol. Imaging 44, 97\u2013110 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"49376_CR32","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2967\/jnumed.111.101733","volume":"53","author":"M Lodge","year":"2012","unstructured":"Lodge, M., Chaudhry, M. A. & Wahl, R. L. Noise considerations for PET quantification using maximum and peak standardized uptake value. J. Nucl. Med. 53(7), 1041\u20131047 (2012).","journal-title":"J. Nucl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49376-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T09:08:35Z","timestamp":1702112915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-49376-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["49376"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-49376-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2154646\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,9]]},"assertion":[{"value":"11 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21838"}}